Ulcerative Colitis & Crohns Results Presented at ECCO
Filed with ASX · · 4 pages · English
Earlier from Mesoblast
- Appendix 4C Quarterly Activity Report
- FDAs OTAT Agrees to Primary Endpoint for Back Pain
- Update on Novartis Agreement
- MSB and Oaktree Conclude Refinancing of Senior Debt Facility
- AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
Later from Mesoblast
- Second Quarter Results Presentation
- S&P DJI Announces March 2022 Quarterly Rebalance
- MSB Q3 Financial Results and Operational Highlights
- Third Quarter Results Presentation
- Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast